ABSTRACT -Embryonic mortality and intrauterine growth retardation (IUGR) are induced by exposure of rodents to xenobiotic agents during the pregastrulation period of development. We examined the time course of the effects of methyl methanesulfonate (MMS), an alkylating agent, on conceptus development in order to clarify the relative roles of the embryo and the placenta in their induction. Pregnant rats were treated orally with a single dose of MMS (200 mg/kg) in the morning of gestation day (GD) 6 (peri-implantation stage). Embryonic mortality was increased on GD12 and thereafter by MMS treatment, with newly dead embryos showing placental hypoplasia at GD12. Embryo or fetal weight was also smaller for MMS-treated dams than for control dams from GD14 to GD20. The labyrinth zone and junctional zone (JZ) of the placenta were thinner in MMS-treated rats from GD12 to GD17 and from GD12 to GD20 (except for GD17), respectively. Furthermore, MMS-treated dams showed a smaller number of glycogen cells in the JZ on GD14. In contrast, the placental glycogen concentration was higher and the expression of glucose transporter 1 in the JZ remained at GD20. These results indicate that exposure of pregnant rats to MMS at the peri-implantation stage of embryogenesis affects placental development and growth. The placental impairment induced by MMS was likely responsible for the embryonic death observed 6 days after exposure of dams to this agent as well as for the IUGR of surviving embryos or fetuses throughout the gestation period.
INTRODUCTION
Pregastrulation mammalian embryos used to be thought to exhibit an all-or-none response to extrinsic chemical or physical agents; The embryo either died during gestation or survived free of malformations (Russell, 1950 (Russell, , 1954 Russell, 1950, 1952) . It was subsequently found, however, that exposure of pregastrulation mouse embryos to various agents, including x-radiation, mutagens or retinoic acid, can result in developmental malformations as well as in embryonic mortality and intrauterine growth retardation (IUGR) (Spielmann and Eibs 1978; Nagao et al., 1986 Nagao et al., , 1991 Nagao et al., , 1997 Nagao et al., , 2000 Generoso et al., 1987 Generoso et al., , 1988 Generoso et al., , 1991 Rutledge et al., 1992 Rutledge et al., , 1994 Nagao, 1994 Nagao, , 1996 Jacquet et al., 1995) . The zygote and subsequent pregastrulation stages of mice are thus susceptible to chemical perturbations that result in abnormal development of the conceptus. However, the sensitivity of embryos and the consequences of their exposure to xenobiotic agents depend on the time during pregastrulation development at which such exposure occurs (Rutledge, 1997) .
Although several developmental toxicological studies have examined the effects of treatment of mouse dams with various agents during the pregastrulation stage, only
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associated with placental alterations in pregnant rats treated with methyl methanesulfonate (MMS) at the peri-implantation stage a few such studies have been performed with rats and other species. Treatment of rats during the pregastrulation stage with mutagens or other compounds has been shown to result in embryonic mortality or IUGR or in developmental abnormalities (Brock and von Kreybig, 1964; Spielmann et al., 1977; Giavini et al., 1984 Giavini et al., , 1990 Yokoi et al., 2007) . Embryonic death and IUGR are thus common consequences of exposure to xenobiotic agents at the pregastrulation stage in rats and mice. Both embryonic death and IUGR are important endpoints in developmental toxicology. In general, low birth weight has been linked to adult-onset diseases (Godfrey and Barker, 2000) . A single intraperitoneal injection of methyl methanesulfonate (MMS), an alkylating agent, in pregnant mice at the zygote or blastocyst stage increases pre-and postimplantation embryonic mortality as well as the incidence of malformations in term fetuses (Generoso et al., 1991; Rutledge et al., 1992; Nagao et al., 1997; Rutledge, 1997) . Treatment of mouse embryos at the 16-cell stage for 1 hr with MMS in vitro resulted in embryonic death and IUGR after their transplantation into the oviduct of female mice (Fabro et al., 1984) . We have previously shown that the consequences for conceptal development of a single oral treatment of rat dams with MMS during the pregastrulation period are dependent on the precise time of such treatment (Yokoi et al., 2007) . Embryonic death after implantation and IUGR for term fetuses were induced by treatment of dams at the peri-implantation stage (the morning of gestation day (GD) 6, with the were rare. Furthermore, MMS treatment on GD6 resulted in a low placental weight at term.
The placenta is responsible for nutrient and gas exchange between the fetal and maternal circulations as well as for maternal endocrine, immune, and metabolic functions that sustain pregnancy (Bauer et al., 1998; Maranghi et al., 1998; Watson and Cross, 2005; Cross, 2006; Moffett and Loke, 2006) . The trophoblast cell lineage arises before implantation of the embryo at the blastocyst stage (Cross, 2000) . Preimplantation development establishes the first two major cell types of the blastocyst, which constitute the trophectoderm and inner cell mass. The cells of the trophectoderm are the first cells of the trophoblast cell lineage and are committed to contribute exclusively to the epithelial portion of the placenta, whereas the inner cell mass gives rise to all of the embryo proper as well as the mesenchymal components of the placenta (Cross, 2001) . In rats, the blastocyst begins to attach to the uterine epithelium during the afternoon of GD4 (Tachi et al., 1970) and begins to adhere to the implantation chamber in the morning of GD5 (Yasuda and Sato, 1980) . The trophoblast begins to invade the endometrium on GD6 (Tachi et al., 1970) , and the trophoblast cells establish direct contact with cells of the stroma on GD7 (Tachi et al., 1970) . The peri-implantation period in rats thus begins at ~18:00 hr on GD4 and ends at ~15:00 hr of GD6 (Aliverti et al., 1982) . After implantation, a yolk sac with an extensive vitelline circulation forms between GD7 and GD11 (Huggett and Pritchard, 1945) . The yolk sac is responsible for a major portion of material transport from mother to conceptus during early organogenesis, before the chorioallantoic placental circulation is established (Beckman et al., 1990) . The chorioallantoic placenta develops from the ectoplacental cone, which results from fusion of the chorion and allantoic mesenchyme in the rat (Maranghi et al., 1998) . On GD10, the distal end of the allantois makes contact with the ectoplacenta (Jollie, 1964 (Jollie, , 1965 . On the next day, embryonic vessels penetrate into the ectoplacental tissue and establish the chorioallantoic placenta (Maranghi et al., 1998) . In rats, the chorioallantoic placenta begins to function on GD12 (Jollie, 1990) .
The rodent chorioallantoic placenta consists of two anatomically and physiologically distinct regions; the labyrinth zone (LZ) and the junctional zone (JZ) (Davis and Glasser, 1968) . The LZ is formed after the attachment of the allantois (mesoderm) to the trophoblast-derived chorion, whereas the JZ (spongiotrophoblast layer) is formed -last-derived ectoplacental cone (Cross, 2000) . The LZ is the principal site of nutrient and gas exchange. Trophoblast cells are positioned between the maternal and fetal blood circulations and play a role in transporting nutrients in the LZ. The JZ, which is located between the LZ and the uterine decidua basalis, is of unknown function but contains spongiotrophoblast cells and glycogen trophoblastic cells. In the rat, the glycogen trophoblastic cells begin to appear in the JZ at around GD13, their number peaks at around GD16, and they have disappeared by the end of pregnancy (Davis and Glasser, 1968) . The placental glycogen content also decreases after GD16 (Goltzsch et al., 1987) .
The glycogen stored in the cytoplasm of glycogen cells of the placenta has been thought to serve as an energy source for the rapidly growing fetus in late pregnancy. Several knockout mouse models in which the number of glycogen cells fails to reach the maximal number of wildtype mice have provided evidence that these cells play a key role in fetal survival and growth (Lopez et al., 1996; Sapin et al., 1997; Robertson et al., 1999) . Given that the rat fetus is incapable of gluconeogenesis, glucose serves as the primary fetal growth substrate (Jones and Rolph, 1985; Girard et al., 1992) . The glucose demands of both fetus and placenta increase with the stage of pregnancy to sustain the rapid fetal growth of mammalian species (Jones, 1991; Hay, 1994; Schneider, 1996) . During late pregnancy, therefore, carbohydrate metabolism is thought to be a key function of the placenta. The facilitative glucose transporter-1 (GLUT1) and -3 (GLUT3) play an important role in the maternal-to-fetal transfer of glucose in the placenta of rats (Zhou and Bondy, 1993; Takata and Hirano, 1997) .
A detailed examination of the placenta would be expected to provide insight into the mechanisms of developmental toxicity, in particular with regard to embryonic mortality and IUGR (Maranghi et al., 1998) . However, little is known of the effects of treatment with xenobiotic compounds at the pregastrulation stage on the relation between placental and embryo-fetal development. To clarify the role of the placenta in developmental toxicity, we have now investigated embryo-fetal and placental development at various gestational stages after MMS administration to rat dams at the peri-implantation stage.
MATERIALS AND METHODS

Animals
All animal experiments were performed in accordance with the Guide to the Care and Use of Experimental Animals of the Toxicology Research Laboratory, Kis-CD(SD)IGS rats were obtained from Charles River Japan (Shiga, Japan). The animals were maintained in a barrier facility at a temperature of 23 ± 2°C and relative humidity of 55 ± 15% and with a 12-hr-light, 12-hr-dark cycle (light on from 08:00 to 20:00 hr). The animals were housed individually in stainless steel mesh cages (260 by 230 by 180 mm) and were allowed free access to tap water and a pellet diet (CE-2; CLEA Japan, Tokyo, Japan) throughout the quarantine, acclimation, and study periods. After the quarantine and acclimation periods, females with a vagImpedance Checker (Muromachi-Kikai, Tokyo, Japan) were selected for mating.
Mating and Treatment
One male rat and one female rat were cohoused in the by the presence of a vaginal plug or of sperm in a vaginal smear on the morning after mating, with this day being designated as GD0. Female rats that had copulated successfully were treated orally with a single dose of MMS (200 mg/kg of body weight) in the morning of GD6. The dose level was the same as our previous study (Yokoi et al., 2007) . MMS (99.9%; Aldrich, Milwaukee, WI, USA) was dissolved freshly in distilled water (JP grade; Otsuka Pharmaceutical Industries, Tokushima, Japan). The control group consisted of untreated dams. Body weight and food consumption of dams were monitored during the gestation period. The dams were anesthetized with diethyl ether for blood sampling and were killed by exsanguination in the afternoon of GDs 7, 10, 12, 14, 17, or 20. The intrathoracic and intraperitoneal organs were observed macroscopically, the ovaries and uterus were removed, and the numbers of corpora lutea and implantations were counted for each side separately. Blood samples were analyzed with the use of a Technicon H·1E system (Bayer-Medical, Tokyo, Japan). Plasma glucose concentration was determined by the mutarotase-glucose oxidase method with the use of an assay kit (Glucose CII-Test; Wako, Osaka, Japan).
Examination of the embryo-fetus and placenta
The terms embryo and fetus are used to encompass the period of organogenesis from GD0 to GD17 and the period from GD17 to GD20, respectively. The uterus includ-10% phosphate-buffered formalin and examined microscopically to assess the viability of the embryos. On GDs 14, 17 and 20, bioscopy of embryos-fetuses was performed macroscopically, and all the surviving embryosfetuses and the placentas were weighed individually. One eight dams at GDs 14, 17, or 20 for determination of glycogen content as described previously (Lo et al., 1970) .
Histopathology of the uterus and placenta
The uterus including conceptuses on GDs 7, 10 and 12 of the implantation sites for three randomly chosen dams on GD7 and for all dams (n = 6 or 7) on GD10 and GD12 were serially sectioned transversely at a thickness of ~5 μm, stained with hematoxylin-eosin and examined microscopically according to standard procedures. The placencut just above the midline with a blade. The cut portion of the placenta was sectioned transversely at a thickness of ~5 μm and stained with hematoxylin-eosin. The thickness dams on GDs 12, 14, 17 and 20 was measured with the use of a light microscope. Alternate sections of the placenta at GD14 and GD20 were also stained with periodic Vol. 33 No. 5 acid-Schiff solution (PAS) to determine the presence and distribution of glycogen. Immunohistochemical analysis of GLUT1 and GLUT3 was also performed with the pla-17 and 20. In brief, the sections were depleted of parafbuffer (pH 6), and heated in a microwave oven for 10 min for antigen retrieval. They were then maintained for 40 min at room temperature, washed with phosphate-buffered saline, treated with 3% H 2 O 2 to inhibit endogenous peroxidase activity, and exposed to 1% bovine serum albumin (Sigma-Aldrich, St. Louis, MO, USA) to block nonspemin at room temperature with rabbit antisera to GLUT1 (Lab Vision, Fremont, CA, USA) or to GLUT3 (ImmunoBiological Laboratories, Takasaki, Japan), respectively. Antisera were diluted 1:200 (GLUT1) or 1:20 (GLUT3) with phosphate-buffered saline. The sections were subsequently incubated with horseradish peroxidase-conjugated secondary antibodies (EnVision; Dako, Carpinteria, CA, USA), exposed to diaminobenzidine, and counterstained with hematoxylin.
Statistical analysis
Data are presented as means ± S.D. unless indicated otherwise. Statistical analysis was performed with the use of Statistical Library I software (Yukms, Tokyo, Japan). Differences in maternal body weight, food consumption, the number of corpora lutea, the number of implantations, the number of live embryos or fetuses, embryo or fetal weight, placental weight, hematologic parameters, glycogen content, and placental thickness were evaluated by Student's t test or Welch's t test after examination of variance with the F test. The Mann-Whitney rank sum test with Yates' correction for ties was used to evaluate differences in pre-or postimplantation loss. The chi-square test was used to analyze the pregnancy rate. A P value of <
RESULTS
Effects of MMS treatment on dams
cant decrease in body weight on GD7 and thereafter compared with control dams (Fig. 1) . However, the gain in body weight from GD7 to term was similar for MMStreated and control dams. Food consumption in MMStreated dams was decreased transiently on GD7 but did -after (Fig. 2) . Blood erythrocyte parameters revealed a slight anemia in MMS-treated dams on GD12 (Table 1) . Plasma glucose levels from GD7 to GD20 did not dif- ( Table 1) .
Effects of MMS on embryonic mortality and intrauterine growth
The uterine content of rats was examined on GDs 7, differences in the rates of pregnancy or preimplantation loss or in the numbers of corpora lutea or implantations between the MMS and control groups at any gestational stage examined. The postimplantation loss on GD10 was also similar in MMS and control groups. However, greater than that in the control group on GD12 and thereafter. Several newly dead embryos were observed in dams of the MMS group on GD12. The number of live embryos in the MMS group on GD14 and thereafter was significantly lower than that in the control group. Embryo-fetal weight in the MMS group was also significantly lower than that in the control group on GDs 14, 17, and 20 -ly lower in the MMS group than in the control group on GD14 and GD20, but not on GD17 (Table 3) .
Effects of MMS on placenta
Histology of the uterus including embryos showed no differences between MMS-treated and control groups on GD7 (data not shown). On GD10, development of the embryo and placenta was retarded in the MMS group compared with that in the control group (Fig. 3) . Newly dead embryos in the MMS group on GD12 showed marked hypoplasia of the placenta (Fig. 4C) . The placenta of live fetuses also manifested altered development in the MMS group on GD12 and thereafter (Table 4, . The thickness of the LZ of the placenta was siggroup on GDs 12, 14 and 17 but not on GD20. The JZ group than in the control group on GDs 12, 14, and 20 but not on GD17. No marked differences were observed in the decidua basalis between the MMS and control groups (Figs. 5A and 5B). In control rats, a large proportion of the JZ of the placenta was occupied by glycogen trophoblast cells on GD14 (Fig. 5C ), but the number of these cells had decreased by GD20 (Fig. 6C ). In contrast, the number of glycogen trophoblast cells in the JZ of MMS-treated rats was smaller than that in control rats on GD14 (Fig. 5D ) and had not decreased markedly by GD20 (Fig. 6D) . The glycogen content of the placenta in the control group, in terms of both the total amount of glycogen per placenta and of the amount per gram of tissue (Table 5 ). In contrast, the amount of glycogen per gram of tissue, but not the total amount per placenta, was group at GD20. Immunohistochemical analysis of the placenta on GD20 revealed the presence of GLUT1-positive cells in the JZ of the MMS group but not in that of the control group (Fig. 7) . No marked difference in GLUT1 expression in the LZ was apparent between rats of the two groups at this time. GLUT1 expression in the JZ or LZ also did not appear to differ between the two groups on GD14 or GD17 (data not shown). No differences in the expression of GLUT3 in the placenta were detected between the MMS and control groups on GDs 14, 17 or 20 (data not shown).
DISCUSSION
We have shown that a single oral administration of MMS to maternal rats on GD6 induced postimplantation embryonic death and IUGR. Newly dead embryos were observed in the MMS-treated rats on GD12, and a sig-MMS-treated group on GD12 and thereafter. The induction of embryonic death may thus occur ~ 6 days after MMS treatment. Histopathologic examination of the uterus and conceptuses also revealed a reduction in the thickness of both the LZ and JZ of the placenta immediately after embryonic death on GD12. IUGR concomitant with placental changes induced by MMS treatment was observed as early as GD14 and continued throughout fetal development.
The placenta plays a pivotal role in fetal growth and survival (Cross, 2006) . Developmental defects of the placenta are associated with embryonic mortality and IUGR (Hay et al., 1997; Cross, 2006) . Functional defects of the placenta also induce IUGR or fetal death depending on their severity (Watson and Cross, 2005) . MMS methylates DNA at the N7 position of guanine and the N3 position of adenine (Pegg, 1984) . Treatment of rat dams with cyclophosphamide, another alkylating agent, at the preimplantation stage (GD3) was previously shown to result in embryonic death and IUGR without embryonic malformation (Spielmann et al., 1977) . Embryonic death increased from 30 to 90% between GD11 and GD14, corresponding to the period of organogenesis. Flushing of blastocysts from dams treated with cyclophosphamide on GD3 and their transplantation into untreated female rats resulted in the formation of a small placental anlage on GD11 but the decidua was unaffected (Spielmann et al., 1977) . The embryonic death resulting from treatment of dams Abbreviations: RBC, red blood cells; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular a Values for GD20 are derived from our previous study (Yokoi et al., 2007) , with the exception of those for glucose concentration. *P < 0.05 versus control group.
with an alkylating agent before gastrulation might thus be attributable to a direct effect on the trophectoderm. Several molecular pathways essential for placental and Cross, 2005) , and mutation of various genes in mice results in embryonic mortality or fetal growth retardation as a result of defects in placental development (Cross, 2000) . MMS has both mutagenic (Moutschen, 1969) and clastogenic (Frei and Venitt, 1975) potential. Intrauterine mortality and IUGR are also associated with chromo- somal abnormalities (Astner et al., 1998; Maulik, 2006) . Treatment of female rats with chlorambucil or cyclophosphamide, both of which are DNA cross-linking agents, during the preimplantation period resulted in the formation of blastocysts with micronuclei (Giavini et al., 1984 (Giavini et al., , 1990 . As far as we are aware, xenobiotic exposure at the peri-implantation stage, before the chorioallantoic placenta is established, has not been shown to induce chromosomal aberrations of the inner cell mass or trophectoderm. MMS treatment at the peri-implantation stage, as in the present study, might thus induce chromosomal damage or mutations in genes that are essential for normal growth and development of the embryo and placenta. Traditional gene-targeting approaches have revealed roles of targeted genes in development of both the fetus and placenta, with null mutations of these genes resulting in embryonic death or IUGR (Han and Carter, 2001 ).
Gene expression during cell differentiation and specialization is controlled both at the level of the DNA sequence itself and at the epigenetic level (Reik et al., 2001) . Epigenetic regulation of imprinted gene expression appears to be less dependent on DNA methylation in the placenta than in the embryo, with repressive histone methylation playing the dominant role in the placenta (Wagschal and Feil, 2006; Hemberger, 2007) . MMS methylates nuclear protein as well as DNA Bolognesi, 1985a, 1985b) . In the present study, MMS exposure during the peri-implantation period had long-lasting effects that resulted in embryonic death. Exposure of the conceptus to MMS at the peri-implantation stage may thus have resulted in aberrant epigenetic reprogramming of the trophectoderm that was responsible for the observed chorioallantoic placental hypoplasia.
In addition to genetic and epigenetic factors, environ- mental factors have been associated with complications of pregnancy outcome ranging from embryonic mortality to IUGR (Cross, 2006) as well as with impaired placental growth (Wu et al., 2006) . Such factors of the maternal environment include nutrient restriction (Woodall et al., 1996; Rudge et al., 1999; Redmer et al., 2004; Wu et al., 2006) , oxidative stress (Maranghi et al., 1998; Nash et al., 2005; Myatt, 2006; Burdon et al., 2007) , anemia (Crowe et al., 1995) , hypoxia (Robinson et al., 1979 (Robinson et al., , 1985 Owens et al., 1987a Owens et al., , 2007 Lynch and Bruce, 1989; Myatt, 2006) , and hypoglycemia (Robinson et al., 1979; Lueder et al., 1992; Carver and Hay, 1995; Owens et al., 1987b Owens et al., , 2007 . Nutrient restriction affects the development of the blastocyst, its implantation, and the subsequent development of the placenta (Cross and Mickelson, 2006) . Chronic maternal undernutrition was shown to induce retardation of both fetal and placental growth in rats (Woodall et al -sient decrease in food intake on GD7 was induced by MMS treatment on GD6. The effects of nutrient restriction depend on the extent and duration of the restriction as well as on the stage of pregnancy (Redmer et al., 2004) . Maternal food restriction was recently shown to have dynamic effects on epigenetic gene regulation (Ferguson-Smith et al., 2006; Nafee et al., 2008) . It is possible that aberrant epigenetic regulation leading to developmental failure was induced by the transient decrease in food intake in the present study.
Hypoxia-reoxygenation resulting in oxidative stress has been shown to be associated with the formation of hydroxynonenal, a marker of lipid peroxidation, in the mouse placenta on embryonic day 16 and thereafter but not on embryonic day 14 (Burdon et al., 2007) . Treatment of rats with MMS induces the synthesis of oxidative stress-responsive proteins (Ashino et al., 2003) . In the present study, however, we treated female rats during the peri-implantation period, before the onset of formation of the chorioallantoic placenta. It is therefore unlikely that oxidative stress at the peri-implantation stage directly affects the subsequent formation and development of the placenta.
Severe anemia in maternal rats results in a reduction in both fetal and placental weight (Crowe et al., 1995) . However, we did not detect a pronounced effect of MMS on erythrocyte parameters, including the hemoglobin level, of dams throughout the gestation period in the present study, although transient and low-level anemia was apparent at GD12.
Maternal hypoxia has been associated with fetal growth retardation and placental hypertrophy as a compensatory response (Lynch and Bruce, 1989) . Fetal growth retardation due to restriction of placental growth after removal of endometrial caruncles is associated with chronic fetal hypoxia in sheep (Robinson et al., 1979 (Robinson et al., , 1985 Owens et al., 1987a Owens et al., , 2007 . Furthermore, the fetal growth failure resulting from restriction of placental growth results in the development of chronic hypoglycemia in the affected fetuses (Robinson et al., 1979 (Robinson et al., , 1985 Owens et al., 1987b) . Expression of GLUT1 and GLUT3 is up-regulated by hypoxia (Esterman et al., 1997; Baumann et al., 2007) . In the present study, we detected GLUT1, but not GLUT3, in the JZ of the placenta of MMS-treated rats on GD20. Treatment of Holtzman rats with 2,3,7,8-tetracholorodibenzo-p-dioxin on GD15 resulted in placental hypoxia and increases in placental glycogen content and the level of GLUT3 mRNA (but not that of GLUT1 mRNA) on GD20 as well as in fetal death (Ishimura et al., 2002a (Ishimura et al., , 2002b . In normal rats, GLUT3 mRNA is restricted to the LZ of the placenta (Zhou and Bondy, 1993; Ishimura et al., 2002a) . Whereas GLUT1 mRNA is abundant in both the LZ and JZ of the placenta on embryonic day 14 (Zhou and Bondy, 1993) , its amount decreases between embryonic days 14 and 20, with this decrease being especially pronounced in the JZ (Zhou and Bondy, 1993) . These findings are consistent with our observations of the placenta of the control group in the present study. We found that the placental LZ of MMS-treated rats exhibited "catch-up" growth toward term; whereas decreased on GDs 12, 14 and 17, it was similar to that of control rats on GD20. In contrast, the time course of the effect of MMS on the thickness of the JZ was similar to decrease on GDs 12, 14 or 20 but not on GD17. Hypoxia of the fetus and placenta at term was thus not likely induced by MMS in the present study because the thickness of the LZ, a key placental area for gas exchange, was normal in MMS-treated rats on GD20. It is not clear why growth of the LZ differs from that of the JZ, but it is likely that MMS restricts rather than retards JZ growth.
The presence of GLUT1 in the placental JZ of MMStreated rats on GD20 may be due to the marked effect of MMS on the JZ in the present study. The placental glycogen content, both the total amount and the amount per rats than in control animals on GD14. In contrast, placental glycogen concentration was higher in the MMS group than in the control group on GD20. The total amount of placental glycogen was similar in both groups of animals on GD20, however, likely because of the thinner JZ and reduced weight of the placenta in the MMS-treated rats. Glycogen trophoblastic cells begin to appear in the JZ of rats around GD13, with their number peaking around GD16, and they disappear by the end of pregnancy (Davis and Glasser, 1968) . The placental glycogen concentration also decreases after GD16 (Goltzsch et al., 1987) . The rate of glucose metabolism is the highest in the JZ of the rat placenta during midgestation and decreases substantially at term, in parallel with GLUT1 expres- sion in the JZ, with GLUT1 being responsible for supplying glucose for use as a placental fuel (Zhou and Bondy, 1993) . The amount of glucose consumed by the placenta is much higher than that consumed by the brain, another tissue with a high glucose demand (Jones, 1991) . IUGR of the fetus due to restriction of placental growth is associated with a reduced utero-placental glucose consumption and a reduced supply of glucose to both the uterus and fetus (Owens et al., 1987b) . The glycogen store and GLUT1 expression remaining in the JZ of the placenta of MMS-treated rats at term may thus be the result of reduced glucose consumption by the placenta associated with the observed placental hypoplasia (especially of the JZ). Long-term insulin-induced maternal hypoglycemia results in growth retardation of both the fetus and placenta (Lueder et al., 1992; Carver and Hay, 1995) . However, MMS had no effect on the plasma glucose level of dams throughout gestation in the present study.
In the present study, embryonic-fetal IUGR was observed throughout gestation in MMS-treated dams and may have been attributable to defects in placental function that disrupt glucose delivery and carbohydrate metabolism. Development of the conceptus is a complex process -mental factors. The effects of peri-implantation MMS treatment on such factors and the role of such effects in the IUGR induced by this agent remain to be characterized.
In conclusion, we have shown that exposure of rat dams to MMS on GD6, during the peri-implantation period and before formation of the chorioallantoic placenta, induced hypoplasia of the placenta. This effect on the placenta was likely responsible for the embryonic mortality apparent 6 days after MMS exposure as well as for the IUGR of surviving fetuses.
